Rahul Gosain, MD

Medical oncologists discuss therapeutic practices for patients with non–small cell lung cancer with ALK mutations.

A thoracic medical oncologist provides insights on the treatment of patients with non–small cell lung cancer with uncommon EGFR mutations.

Balazs Halmos, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for patients with non–small cell lung cancer (NSCLC) with common sensitizing EGFR mutations.

The Oncology Brothers and Eric Singhi, MD, provide clinical insights on the treatment of patients with small cell lung cancer with driver mutations.

Eric Singhi, MD, joins the Oncology Brothers to discuss adverse event management practices for patients with small cell lung cancer.

Medical oncologists provide comprehensive insights on treatment practices for patients with extended-stage small cell lung cancer.

Following recent data from the ADRIATIC study, the Oncology Brothers and Eric Singhi, MD, discuss the role of prophylactic cranial irradiation (PCI) in patients with small cell lung cancer.

Eric Singhi, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for patients with limited-stage small cell lung cancer (SCLC), highlighting the ADRIATIC study.

Naveen Pemmaraju, MD, discusses adverse effects associated with JAK inhibitors in the treatment of myelofibrosis, and the Oncology Brothers recap the entire discussion.

An expert on myelofibrosis discusses anemia and splenomegaly management practices for patients with myelofibrosis.

Naveen Pemmaraju, MD, gives a comprehensive overview of JAK inhibitors available for the treatment of patients with myelofibrosis.

A hematology specialist provides clinical insights on supportive care practices for patients with myelofibrosis.

Naveen Pemmaraju, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss diagnostic practices and prognostic factors for patients with myelofibrosis.

Samer Al'Hadidi, MD, offers advice to community oncologists who treat patients with relapsed/refractory multiple myeloma, and the Oncology Brothers recap the entire discussion.

Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Samer Al'Hadidi, MD, to discuss treatment decision-making strategies for patients with relapsed/refractory multiple myeloma.

In a discussion with the Oncology Brothers on the treatment of patients with relapsed/refractory multiple myeloma, Samer Al'Hadidi, MD, discusses adverse effects associated with CAR T-cell therapy and bispecific antibodies.

An expert on the treatment of multiple myeloma discusses the role of CAR T-cell therapy in relapsed/refractory disease.

Samer Al'Hadidi, MD, discusses monitoring strategies for patients with relapsed/refractory multiple myeloma who are receiving lenalidomide.

The panel discusses adverse effects associated with stereotactic body radiation therapy, and the Oncology Brothers provide a recap of the entire discussion.

Focusing on liver-directed therapy, the panel provides clinical insights on the treatment of patients with hepatocellular carcinoma who have liver-confined disease and are not candidates for transplant.

Providing the interventional radiologist perspective, Harris Chengazi, MD, gives an overview of available treatment strategies.

Radiation oncologists Nina Sanford, MD, and Jeffrey M. Ryckman, MD, provide an overview of treatment modalities, highlighting SRS, SBRT, proton therapy, and how options have improved.

Caitlin Costello, MD, offers concluding remarks and guidance to healthcare providers on optimizing multiple myeloma patient care.

A medical expert shares her treatment approach for a high-risk multiple myeloma patient, considering transplant eligibility, dose escalations, and maintenance therapy based on induction regimen and patient risk factors.

Caitlin Costello, MD, shares insights on the role of minimal residual disease (MRD) assessment in the multiple myeloma treatment process, including its impact on induction therapy and disease monitoring.

A medical expert discusses tailoring treatment strategies for standard-risk and high-risk multiple myeloma patients, considering patient characteristics and transplant eligibility when selecting treatment combinations.

Caitlin Costello, MD, explores the evolving role of biomarkers in the early diagnosis and treatment of multiple myeloma, highlighting their impact on the changing landscape of the disease.

Nitin Jain, MD, discusses a novel treatment approach for chronic lymphocytic leukemia, along with stem cell transplantation and other later-line therapies and treatment options for managing CLL.

Nitin Jain, MD, discusses the increasing use of various Bruton's tyrosine kinase inhibitors as front-line treatment options for patients with chronic lymphocytic leukemia.

Nitin Jain, MD, presents data on the efficacy of various chronic lymphocytic leukemia treatments, reviews current guidelines, discusses the increasing use of Bruton's tyrosine kinase inhibitors and the decreasing role of chemotherapy in his practice. He emphasizes the importance of considering patient factors and preferences in treatment decision-making.